Sabby Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Sabby Management’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-224	Closed	-$72K	–	131
2020 Q1	$72K	Sell	224 -206	-48%	-$101K	0.03%	73
2019 Q4	$278K	Buy	430 +11	+3%	+$7.46K	0.08%	43
2019 Q3	$461K	Buy	419 +110	+36%	+$122K	0.25%	41
2019 Q2	$342K	Buy	+309	New	+$537K	0.43%	42
2018 Q3	–	Sell	-33	Closed	-$206K	–	151
2018 Q2	$206K	Sell	33 -10	-23%	-$106K	0.03%	100
2018 Q1	$549K	Buy	+43	New	+$1.15M	0.07%	92
2017 Q3	–	Sell	-2	Closed	-$103K	–	220
2017 Q2	$103K	Hold	2	–	–	0.01%	194
2017 Q1	$133K	Buy	+2	New	+$160K	0.01%	231

Other funds holding CYTO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sabby Management's CYTO Position: Q2 2020 in Review

Sabby Management sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2020, closing a stake of 224 shares — an estimated $72K sold.

Sabby Management first reported a position in CYTO in Q1 2017 and held it in 8 quarters. The position peaked at $549K in Q1 2018. 4 funds tracked by Wall St. Rank hold CYTO as of Q2 2020.

Sabby Management reported no remaining Altamira Therapeutics Ltd position as of Q2 2020 after selling out during the quarter.
Sabby Management sold 224 Altamira Therapeutics Ltd shares in Q2 2020, an estimated $72K.
Sabby Management first reported a position in Altamira Therapeutics Ltd in Q1 2017 and held it in 8 quarters.
Sabby Management's Altamira Therapeutics Ltd position peaked at $549K in Q1 2018.
4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.